INSMED (INSM) FY2025 10-K Risk Factors: 15 New, 4 Dropped

What the changes say

BRINSUPRI joins ARIKAYCE as an approved-product dependency, expanding market-acceptance and commercialization risk to both products.
ARIKAYCE’s ENCORE trial enrolled 425 patients, but subjective QOL-B assessments and FDA timing still threaten full approval.
New risks emphasize Lamira approvals, generic competition, TPIP manufacturing, FDA changes, and evolving gene-therapy oversight.
Accumulated deficit reached $5.6 billion and 2025 net loss $1,276.8 million; profitability is not expected for the foreseeable future.

What changed since the prior 10-K

New

New
Our prospects are highly dependent on the success of our approved products, ARIKAYCE and BRINSUPRI
Failure to commercialize or maintain approval for ARIKAYCE and BRINSUPRI could materially damage Insmed’s growth, finances, prospects, and stock value.
New
The confirmatory clinical trial program is intended to fulfill the FDA’s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCE
Delays, FDA dissatisfaction, or subjective QOL-B results in the 425-patient ENCORE trial could prevent ARIKAYCE’s full approval.
New
If our estimates of the size of the potential markets for ARIKAYCE, BRINSUPRI, or our product candidates prove inaccurate, our ability to generate revenue may be materially adversely affected
Overstated market estimates or inaccurate identification of physicians treating MAC lung disease could limit revenue from ARIKAYCE, BRINSUPRI, and candidates.
New
Our estimates of the potential addressable market for TPIP in PAH and PH-ILD in the US, the European 5 and Japan were also derived from external sources. However, the studies we reviewed indicate a lack of consensus on prevalence rates
Conflicting prevalence data and healthcare-provider guidelines could overstate TPIP’s, ARIKAYCE’s, BRINSUPRI’s, or other candidates’ addressable markets and reduce use.
NewRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
As ARIKAYCE is a drug/device combination product, we cannot sell ARIKAYCE without Lamira
ARIKAYCE depends on approved Lamira delivery systems, while TPIP may also require device approvals that are unavailable in some markets.
NewRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
If we fail to obtain or maintain regulatory exclusivity for our product candidates, our business may be materially harmed
Limited regulatory exclusivity, including BRINSUPRI’s inability to block certain 505(b)(1) applications, could allow competing products sooner.
NewRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
Generic competition following the expiration or loss of exclusivity may significantly reduce our revenues
Paragraph IV challenges and generic or follow-on approvals before patent or exclusivity expiry could cause costly litigation and earlier revenue loss.
NewRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
CBER has experienced leadership changes and broad layoffs and departures under the Trump Administration, which may slow review times
CBER leadership changes, layoffs, and evolving gene-therapy guidance under the Trump Administration could slow reviews and complicate product development.
NewRisks Related to Our Reliance on Third Parties
If we are unable to form and sustain relationships with third-party service providers that are critical to our business, or if any third-party arrangements that we may enter into are unsuccessful, our ability to develop and commercialize our products may be materially adversely affected
Insmed relies heavily on named manufacturers, CROs, laboratories, and other providers for ARIKAYCE, Lamira, BRINSUPRI, TPIP, and clinical programs.
NewRisks Related to Our Reliance on Third Parties
We also will be reliant on CMOs to manufacture supply of TPIP for our future requirements. We plan to enter into commercial agreements with CMOs for TPIP, and cannot guarantee that we will be able to locate adequate partners or enter into favorable agreements with them
Insmed may be unable to secure suitable, affordable CMOs for TPIP, whose novel gene-therapy manufacturing could face capacity, yield, cost, and compliance problems.
NewRisks Related to Our Reliance on Third Parties
Adverse consequences to our business may result if we or our manufacturing partners fail to comply with applicable regulations or maintain required approvals
Insmed or manufacturing partners could violate cGMP, quality-system, or other requirements, triggering inspections, deficiencies, approval problems, or supply disruption.
NewRisks Related to Our Intellectual Property
If we do not obtain patent term extension for BRINSUPRI or our product candidates, if needed, our business may be harmed
Failure to obtain available Hatch-Waxman patent-term extensions for BRINSUPRI or candidates could shorten protection and harm future revenue.
NewRisks Related to Our Intellectual Property
If we fail to comply with obligations in our third-party agreements, our business may be adversely affected, including by the loss of license rights that are important to our business
NewRisks Related to Government Regulation
It also remains unclear how GENEROUS, GUARD or any other new legislation or regulation might affect the prices we may obtain for ARIKAYCE, BRINSUPRI, or any of our product candidates for which regulatory approval is obtained
NewRisks Related to Government Regulation
We are subject to anti-corruption laws and trade control laws, as well as other laws governing our operations

Dropped

Dropped
If estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP, or our other product candidates are overstated or data we have used to identify physicians is inaccurate, our ability to earn revenue to support our business could be materially adversely affected
Dropped
We may not be successful in clinical trials or in obtaining regulatory approvals required to expand the indication for ARIKAYCE, which may materially adversely affect our prospects and the value of our common stock
DroppedRisks Related to Our Reliance on Third Parties
These risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock
DroppedRisks Related to Our Reliance on Third Parties
The manufacturing facilities of our third-party manufacturers are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we and our manufacturing partners fail to comply with the regulations or maintain the approvals

Reworded

91% rewrittenRisks Related to Government Regulation
Our industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results
The discussion now covers Medicare and Medicaid changes, federal drug-price negotiation, EU and Japan reforms, and Trump Administration changes to FDA oversight.
78% rewrittenRisks Related to Ownership of Our Common Stock
Our shareholders may experience dilution of their ownership interests because of the future issuance of additional shares of our common stock
The risk no longer specifically highlights conversion of the 2028 Convertible Notes and instead emphasizes dilution and downward pressure from any new shares.
Was: Our shareholders may experience dilution of their ownership interests because of the future issuance of additional shares of our common stock for general corporate purposes and upon the conversion of the 2028 Convertible Notes
76% rewritten
We obtained regulatory approval of ARIKAYCE in the US through an accelerated approval process, and full approval will be contingent on successful and timely completion of a confirmatory post-marketing clinical trial
The updated wording retains ARIKAYCE’s accelerated-approval and confirmatory-trial risk while adding more detail on the FDA’s approval criteria.
66% rewrittenRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
Our clinical and pre-clinical research activities include the research and development of novel gene therapy product candidates
The risk now covers ongoing gene-therapy clinical trials in addition to planned preclinical programs.
Was: Our pre-clinical research activities include the research and development of novel gene therapy product candidates
65% rewrittenRisks Related to Our Financial Condition and Need for Additional Capital
We have a history of operating losses, expect to incur operating losses in the near term, and may never achieve or maintain profitability
Loss figures increased to a $5.6 billion accumulated deficit and $1,276.8 million 2025 net loss, with profitability deferred for the foreseeable future.
Was: We have a history of operating losses, expect to incur operating losses for the foreseeable future and may never achieve or maintain profitability
57% rewritten
The commercial success of ARIKAYCE and BRINSUPRI depend on market acceptance by physicians, patients, third-party payors and others in the healthcare community, and the commercial success of our product candidates, if approved, may similarly depend on market acceptance
BRINSUPRI was added alongside ARIKAYCE, including its FDA and EC approvals and product-specific safety and acceptance considerations.
Was: The commercial success of ARIKAYCE depends on continued market acceptance by physicians, patients, third-party payors and others in the healthcare community and the commercial success of brensocatib, TPIP, or our other product candidates, if approved, will similarly depend on market acceptance
50% rewrittenRisks Related to the Operation of our Business
We are subject to laws and regulations that govern how we can collect, process, store, and transfer personal data and sensitive data, and violations may result in meaningful penalties, enforcement, and/or reputational harm and have a significant impact on our operations
The risk now includes genetic privacy laws and DOJ rules on bulk US health and genomic data, especially as international operations expand.
Was: We are subject to data privacy laws and regulations that govern how we can collect, process, store, and transfer personal data, and violations can result in meaningful penalties, enforcement, and/or reputational harm and have a significant impact on our operations
47% rewritten
We are subject to substantial, ongoing regulatory requirements, including with respect to advertising and promotion, and failure to comply with these requirements may lead to enforcement action or otherwise materially harm our business
The requirements now expressly cover drug cGMP, distribution-supply-chain security, and reporting obligations, alongside existing promotion and manufacturing controls.
Was: We remain subject to substantial, ongoing regulatory requirements, and failure to comply with these requirements could lead to enforcement action or otherwise materially harm our business
45% rewritten
We may not be able to obtain regulatory approval for ARIKAYCE in front-line NTM lung disease, for ARIKAYCE or BRINSUPRI in additional markets or for our product candidates
Was: We may not be able to obtain regulatory approvals for brensocatib, or for our other product candidates and we may not be able to receive approval for ARIKAYCE in front-line NTM lung disease or in new markets
43% rewrittenRisks Related to Our Intellectual Property
We may not be able to enforce our intellectual property rights throughout the world, which may harm our business
Was: We may not be able to enforce our intellectual property rights throughout the world, which could harm our business
43% rewrittenRisks Related to Our Reliance on Third Parties
We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE, Lamira, BRINSUPRI, or our product candidates to meet our required supply for commercialization or clinical studies, which may materially harm our business
Was: We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE, Lamira or our product candidates to meet our required supply for commercialization or clinical studies, which would materially harm our business
41% rewrittenRisks Related to Our Reliance on Third Parties
We do not have long-term commercial agreements with all of our suppliers and if any of our suppliers are unable or unwilling to perform for any reason, we may not be able to locate suppliers or enter into favorable agreements with them
40% rewrittenRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
Pharmaceutical research and development is very costly and highly uncertain, and we may not succeed in developing product candidates in the future
37% rewrittenRisks Related to Our Financial Condition and Need for Additional Capital
Changes in our effective income tax rate and future changes to US and non-US tax laws may adversely affect our results of operations
Was: Changes in our effective income tax rate and future changes to US and non-US tax laws could adversely affect our results of operations
37% rewrittenRisks Related to the Operation of our Business
Any acquisitions we have made or may make in the future, or collaborative relationships we have entered into or may enter into in the future, may not be clinically or commercially successful, and may require financing or a significant amount of cash, which may adversely affect our business
Was: Any acquisitions we make, or collaborative relationships we enter into, may not be clinically or commercially successful, and may require financing or a significant amount of cash, which could adversely affect our business
35% rewrittenRisks Related to Government Regulation
Our research, development and manufacturing activities used in the production of ARIKAYCE, BRINSUPRI, and our product candidates involve the use of hazardous materials, which may expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition
Was: Our research, development and manufacturing activities used in the production of ARIKAYCE and our product candidates involve the use of hazardous materials, which could expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition
35% rewrittenRisks Related to the Operation of our Business
We are subject to a number of risks associated with our international activities and operations and may not be successful in any efforts to further expand internationally
Was: We have limited experience operating internationally, are subject to a number of risks associated with our international activities and operations and may not be successful in our efforts to expand internationally
34% rewritten
ARIKAYCE, BRINSUPRI, or any of our product candidates may develop unexpected safety or efficacy concerns, which may have a material adverse effect on us
Was: ARIKAYCE, brensocatib, TPIP, or our other product candidates could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us
34% rewrittenRisks Related to the Operation of our Business
We expect to continue to expand our development, regulatory and sales and marketing capabilities and, as a result, may encounter difficulties in managing our growth, which may disrupt our operations
Was: We expect to continue to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations
34% rewrittenRisks Related to the Operation of our Business
We have a limited number of significant customers and losing any of them may have an adverse effect on our financial condition and results of operations
Was: We have a limited number of significant customers and losing any of them could have an adverse effect on our financial condition and results of operations
30% rewrittenRisks Related to Our Financial Condition and Need for Additional Capital
We may need to raise additional funds to continue our operations, and any failure to obtain capital when needed on acceptable terms, or at all, may force us to delay, reduce, or eliminate our development programs, commercialization efforts or other operations
Was: We may need to raise additional funds to continue our operations, and any failure to obtain capital when needed on acceptable terms, or at all, could force us to delay, reduce, or eliminate our development programs, commercialization efforts or other operations
28% rewrittenRisks Related to the Operation of our Business
Deterioration in general economic conditions in the US, Europe, Japan and globally, including the effect of prolonged periods of inflation on our suppliers, third-party service providers and potential partners, may harm our business and results of operations
Was: Deterioration in general economic conditions in the United States, Europe, Japan and globally, including the effect of prolonged periods of inflation on our suppliers, third-party service providers and potential partners, could harm our business and results of operations
28% rewrittenRisks Related to the Development and Regulatory Approval of Our Product Candidates Generally
If another party obtains orphan drug exclusivity for a product that is considered the same or essentially the same as a product we are developing for a particular indication, we may be precluded from or delayed in commercializing the product in that indication
Was: If another party obtains orphan drug exclusivity for a product that is considered the same or essentially the same as a product we are developing for a particular indication, we may be precluded or delayed from commercializing the product in that indication
22% rewrittenRisks Related to the Operation of our Business
We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully
22% rewrittenRisks Related to the Operation of our Business
Our inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology may have a material adverse effect on our business or results of operations
Was: Our inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology could have a material adverse effect on our business or results of operations
22% rewrittenRisks Related to the Operation of our Business
Our current and potential future use of AI and machine learning may not be successful and presents new risks and challenges to our business
Was: Our current and potential future use of artificial intelligence (AI) and machine learning may not be successful and presents new risks and challenges to our business
22% rewrittenRisks Related to the Operation of our Business
We are dependent on retaining and attracting key personnel, the loss of whose services may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
Was: We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
21% rewrittenRisks Related to the Operation of our Business
We may be subject to product liability claims, and we have only limited product liability insurance

All 52 risk factors

Headings as the filing states them, in filing order.

Other

01Our prospects are highly dependent on the success of our approved products, ARIKAYCE and BRINSUPRINew
02We may not be able to obtain regulatory approval for ARIKAYCE in front-line NTM lung disease, for ARIKAYCE or BRINSUPRI in additional markets or for our product candidates45% rewritten
03The commercial success of ARIKAYCE and BRINSUPRI depend on market acceptance by physicians, patients, third-party payors and others in the healthcare community, and the commercial success of our product candidates, if approved, may similarly depend on market acceptance57% rewritten
04We obtained regulatory approval of ARIKAYCE in the US through an accelerated approval process, and full approval will be contingent on successful and timely completion of a confirmatory post-marketing clinical trial76% rewritten
05The confirmatory clinical trial program is intended to fulfill the FDA’s post-marketing requirement to allow for full approval of ARIKAYCE by the FDA, and verification and description of clinical benefit in the ENCORE trial will be necessary for full approval of ARIKAYCENew
06We are subject to substantial, ongoing regulatory requirements, including with respect to advertising and promotion, and failure to comply with these requirements may lead to enforcement action or otherwise materially harm our business47% rewritten
07ARIKAYCE, BRINSUPRI, or any of our product candidates may develop unexpected safety or efficacy concerns, which may have a material adverse effect on us34% rewritten
08If our estimates of the size of the potential markets for ARIKAYCE, BRINSUPRI, or our product candidates prove inaccurate, our ability to generate revenue may be materially adversely affectedNew
09Our estimates of the potential addressable market for TPIP in PAH and PH-ILD in the US, the European 5 and Japan were also derived from external sources. However, the studies we reviewed indicate a lack of consensus on prevalence ratesNew

Risks Related to the Development and Regulatory Approval of Our Product Candidates Generally

10Pharmaceutical research and development is very costly and highly uncertain, and we may not succeed in developing product candidates in the future40% rewritten
11As ARIKAYCE is a drug/device combination product, we cannot sell ARIKAYCE without LamiraNew
12Such circumstances would impair our ability to commercialize our products and harm our business and results of operations
13If another party obtains orphan drug exclusivity for a product that is considered the same or essentially the same as a product we are developing for a particular indication, we may be precluded from or delayed in commercializing the product in that indication28% rewritten
14If we fail to obtain or maintain regulatory exclusivity for our product candidates, our business may be materially harmedNew
15Generic competition following the expiration or loss of exclusivity may significantly reduce our revenuesNew
16Our clinical and pre-clinical research activities include the research and development of novel gene therapy product candidates66% rewritten
17CBER has experienced leadership changes and broad layoffs and departures under the Trump Administration, which may slow review timesNew

Risks Related to Our Reliance on Third Parties

18If we are unable to form and sustain relationships with third-party service providers that are critical to our business, or if any third-party arrangements that we may enter into are unsuccessful, our ability to develop and commercialize our products may be materially adversely affectedNew
19We may not have, or may be unable to obtain, sufficient quantities of ARIKAYCE, Lamira, BRINSUPRI, or our product candidates to meet our required supply for commercialization or clinical studies, which may materially harm our business43% rewritten
20We also will be reliant on CMOs to manufacture supply of TPIP for our future requirements. We plan to enter into commercial agreements with CMOs for TPIP, and cannot guarantee that we will be able to locate adequate partners or enter into favorable agreements with themNew
21We do not have long-term commercial agreements with all of our suppliers and if any of our suppliers are unable or unwilling to perform for any reason, we may not be able to locate suppliers or enter into favorable agreements with them41% rewritten
22Adverse consequences to our business may result if we or our manufacturing partners fail to comply with applicable regulations or maintain required approvalsNew

Risks Related to the Operation of our Business

23We are dependent on retaining and attracting key personnel, the loss of whose services may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock22% rewritten
24We expect to continue to expand our development, regulatory and sales and marketing capabilities and, as a result, may encounter difficulties in managing our growth, which may disrupt our operations34% rewritten
25Any acquisitions we have made or may make in the future, or collaborative relationships we have entered into or may enter into in the future, may not be clinically or commercially successful, and may require financing or a significant amount of cash, which may adversely affect our business37% rewritten
26We may be subject to product liability claims, and we have only limited product liability insurance21% rewritten
27We are subject to laws and regulations that govern how we can collect, process, store, and transfer personal data and sensitive data, and violations may result in meaningful penalties, enforcement, and/or reputational harm and have a significant impact on our operations50% rewritten
28Our inability to access, upgrade or expand our technology systems or difficulties in updating our existing technology or developing or implementing new technology may have a material adverse effect on our business or results of operations22% rewritten
29We are subject to a number of risks associated with our international activities and operations and may not be successful in any efforts to further expand internationally35% rewritten
30We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully22% rewritten
31We have a limited number of significant customers and losing any of them may have an adverse effect on our financial condition and results of operations34% rewritten
32Deterioration in general economic conditions in the US, Europe, Japan and globally, including the effect of prolonged periods of inflation on our suppliers, third-party service providers and potential partners, may harm our business and results of operations28% rewritten
33The emergence of a pandemic, and efforts to reduce its spread, may negatively impact our business and operations
34Our current and potential future use of AI and machine learning may not be successful and presents new risks and challenges to our business22% rewritten

Risks Related to Our Intellectual Property

35If we are unable to protect our intellectual property rights adequately, the value of ARIKAYCE, BRINSUPRI, and our product candidates may be materially diminished
36If we do not obtain patent term extension for BRINSUPRI or our product candidates, if needed, our business may be harmedNew
37If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of ARIKAYCE, BRINSUPRI, and our product candidates may be materially diminished
38We may not be able to enforce our intellectual property rights throughout the world, which may harm our business43% rewritten
39If we fail to comply with obligations in our third-party agreements, our business may be adversely affected, including by the loss of license rights that are important to our businessNew

Risks Related to Government Regulation

40Healthcare legislation or other government action may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
41Our industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results91% rewritten
42It also remains unclear how GENEROUS, GUARD or any other new legislation or regulation might affect the prices we may obtain for ARIKAYCE, BRINSUPRI, or any of our product candidates for which regulatory approval is obtainedNew
43We are subject to anti-corruption laws and trade control laws, as well as other laws governing our operationsNew
44Our research, development and manufacturing activities used in the production of ARIKAYCE, BRINSUPRI, and our product candidates involve the use of hazardous materials, which may expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition35% rewritten

Risks Related to Our Financial Condition and Need for Additional Capital

45We have a history of operating losses, expect to incur operating losses in the near term, and may never achieve or maintain profitability65% rewritten
46We may need to raise additional funds to continue our operations, and any failure to obtain capital when needed on acceptable terms, or at all, may force us to delay, reduce, or eliminate our development programs, commercialization efforts or other operations30% rewritten
47We may be unable to use certain of our net operating losses and other tax assets
48Changes in our effective income tax rate and future changes to US and non-US tax laws may adversely affect our results of operations37% rewritten
49We have recorded a significant amount of goodwill on our consolidated balance sheet as a result of acquisitions. We review the recoverability of goodwill annually and whenever events or circumstances indicate that the carrying value of a reporting unit may not be recoverable

Risks Related to Ownership of Our Common Stock

50Our shareholders may experience dilution of their ownership interests because of the future issuance of additional shares of our common stock78% rewritten
51The market price of our stock has been and may continue to be highly volatile, which may lead to shareholder litigation against us
52Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements with our employees may hamper a third party’s acquisition of us or discourage a third party from attempting to acquire control of us, or limit the price that investors might be willing to pay for shares of our common stock

Other INSMED 10-Ks

FY2024 10-K risk factors
40 risks
ARIKAYCE’s commercial acceptance and safety remain central, while brensocatib, TPIP and other pipeline programs face approval and development uncertainty.
Filed Feb 20, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.